Search Bar & Filters
Found 4 Actively Recruiting clinical trials
Actively Recruiting
Stroke is one of the leading causes of death worldwide, with ischemic stroke being the most common type. Researchers are evaluating whether early administration of oral aspirin after intravenous thrombolysis improves functional outcomes for patients with acute ischemic stroke. The study aims to determine if starting aspirin treatment within 3 hours of thrombolysis can prevent neurological deterioration without increasing bleeding risks. Participants are randomly assigned to one of two groups the interventional group receives 300 mg of oral aspirin shortly after starting intravenous thrombolysis, while the control group receives a placebo. Both groups receive the best standard medical care according to current guidelines. Aspirin tablets may be chewed or given via a nasogastric tube if swallowing is difficult. The treatment is administered within 3 hours of initiating thrombolysis. During the study, participants are monitored for neurological improvements and potential complications using scales like the modified Rankin scale and NIH Stroke Scale at various time points up to 90 days after stroke. Researchers will assess functional outcomes, neurological changes, and safety measures, including the risk of intracranial hemorrhage. The total follow-up period extends to 90 days post-stroke.
Actively Recruiting
Healthy Volunteer
Researchers are studying whether providing free glasses for near andor distance vision problems can slow cognitive decline in older adults aged 60 to 79 who live in rural areas and have normal baseline cognition and hearing. The study aims to compare cognitive decline over 36 months between those receiving vision correction and those who do not, also examining cost-effectiveness and different baseline vision needs. Participants randomly assigned to the intervention group will receive free customized glasses based on their prescription and pupillary distance, with yearly eye exams and updated prescriptions as needed. The control group will receive a prescription but no free glasses during the study free glasses will be provided to them after the study ends. Participants can choose from various frames, and replacement glasses will be supplied in case of loss or damage. Throughout the 36-month study, participants will undergo assessments of global and specific cognitive functions, falls risk, vision-related and health-related quality of life, depressive symptoms, physical activity, and social networks at baseline and at 12, 24, and 36 months. Researchers will also measure the cost-effectiveness of the intervention. Participants will be monitored yearly for vision changes, and adherence to glasses use will be supported. Total participation lasts 3 years.
Actively Recruiting
Researchers are studying patients who have had an acute ischemic stroke caused by a blockage in a large blood vessel in the brain. The trial focuses on the safety and effectiveness of remote ischemic conditioning RIC as an additional treatment to improve recovery after endovascular thrombectomy, a procedure that removes the blockage. This research addresses the challenge that even when blood flow is restored, many patients still have poor outcomes or die, possibly due to brain injury during and after the procedure. The study compares three groups one receiving only endovascular thrombectomy and best medical care, a second group receiving thrombectomy plus RIC treatment for 14 days, and a third group receiving thrombectomy plus RIC for 30 days. RIC is a noninvasive device treatment where a cuff on the upper arm inflates and deflates in cycles, applied once before thrombectomy and twice daily afterward. Best medical management follows clinical guidelines for all groups. Participants will be monitored closely for 90 days after stroke. Researchers will assess recovery using the modified Rankin Scale to measure functional independence and will record neurological improvements, brain infarct size, adverse events, and quality of life. The study includes imaging, neurological exams, and safety checks at multiple time points, including 24 hours, 14 days, 72 hours, and 90 days post-treatment to evaluate the impact of RIC on stroke outcomes.
Actively Recruiting
Researchers are investigating the best approach to treat acute ischemic stroke caused by large vessel occlusion LVO, a leading cause of disability. Mechanical thrombectomy MT is the current standard treatment, but the role of intravenous thrombolysis before MT is unclear. This phase 3 randomized trial evaluates different thrombolysis strategies using tenecteplase or reteplase compared with direct MT alone in adults presenting within 4.5 hours of stroke onset with confirmed anterior circulation LVO. Participants will be randomly assigned to one of three groups tenecteplase plus MT, reteplase plus MT, or direct MT without thrombolysis. Tenecteplase is given as a single intravenous bolus dose of 0.25 mgkg, while reteplase is administered as two 18 mg bolus injections separated by 30 minutes. Mechanical thrombectomy is performed according to standard practice. The study aims to determine if bridging thrombolysis improves functional independence at 90 days after treatment, with further comparison between the two thrombolytic agents if superiority is found. Throughout the study, participants will be assessed for functional outcomes, neurological improvement, reperfusion success, quality of life, and safety measures up to 90 days after randomization. Assessments include imaging, clinical evaluations, and monitoring for complications such as bleeding or mortality. The primary outcome is achieving functional independence, defined by a modified Rankin Scale score of 0 to 2 at 90 days. The total study duration extends to the final follow-up at 90 days post-treatment.